title: Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration.
abstract: OBJECTIVE
  This study was conducted to evaluate the possible clinical and genetic indicators for an early response to intravitreal ranibizumab (IVR) in exudative age-related macular degeneration (AMD).
  
  
  METHODS
  The records of 120 eyes from 120 Japanese patients with treatment-naive exudative AMD were retrospectively reviewed. Three consecutive IVR treatments were performed every month. Achievement of anatomical resolution was evaluated by ophthalmoscopy and optical coherence tomography. Multivariable logistic regression analysis was conducted by analyzing SNPs in the ARMS2 locus (A69S) and in the CFH gene (I62V and Y402H), in addition to clinical factors.
  
  
  RESULTS
  The mean central retinal thickness of overall patients was significantly decreased (-120.1 ± 122.8 µm, p = 2.7 × 10(-19)) at 3 months after the initial treatment. In the logistic regression analysis, the poor anatomical resolution of the lesion at 3 months was associated with the combination of CFH I62V + CFH Y402H variants (p = 0.0021), and the polypoidal choroidal vasculopathy lesions (p = 0.044).
  
  
  CONCLUSIONS
  The CFH variants and the polypoidal choroidal vasculopathy lesion may influence the early anatomical resolution with IVR in exudative AMD.
authors.affiliation: Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
authors.forename: Wataru
authors.initials: W
authors.lastname: Matsumiya
authors.forename: Shigeru
authors.initials: S
authors.lastname: Honda
authors.forename: Suiho
authors.initials: S
authors.lastname: Yanagisawa
authors.forename: Akiko
authors.initials: A
authors.lastname: Miki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Nagai
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Tsukahara
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D044466:Asian People / Q000235:genetics; D017242:Complement Factor H / Q000235:genetics; D005260:Female; D006801:Humans; D058449:Intravitreal Injections / Q000379:methods; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011506:Proteins / Q000235:genetics; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects; D012189:Retrospective Studies
chemical_list: C514392:ARMS2 protein, human; D061067:Antibodies, Monoclonal, Humanized; D011506:Proteins; D017242:Complement Factor H; D000069579:Ranibizumab
keywords: 3 months results; age-related macular degeneration; age-related maculopathy susceptibility 2; anatomical outcome; complement factor H; ranibizumab; single nucleotide polymorphism